TollereBio was founded to commercialize the BECC Technology planform for adjuvant development invented by Dr. Robert K. Ernst at the University of Maryland, Baltimore. The BECC platform enables quick and efficient engineering of lipid A mimetics for identification of new TLR4 adjuvants with customized immunostimulatory properties. Our team of experienced industry veterans is excited to offer accessible, cost-effective vaccine adjuvants that can have a positive impact on global human health.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Tollerebio Questions
Tollerebio's LinkedIn profile is https://www.linkedin.com/company/tollerebio
Tollerebio has
3 employees.
View email and phone details for 3
employees at Tollerebio.
Tollerebio's industry is
Biotechnology Research
Tollerebio's top competitors are
Targetrna Inc.,
Aryte Bioscience, Llc,
Open Problems In Single-Cell Analysis,
Abwiz Bio Inc,
Escalier Biosciences B.v.,
Pataigin,
Nantbio,
Cogenesis, Inc.,
Tidewave Bio,
Immunecyte, Inc..
Tollerebio's categories are Biotechnology Research
Tollerebio's founding year is 2023
